Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Mehul Desai, James Kenney & Edmund Pezalla. (2024) Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system. Current Medical Research and Opinion 0:0, pages 1-12.
Read now
Read now
Andreas Schneider, Reto Jost, Christoph Jordi & Jakob Lange. (2023) Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions. Expert Opinion on Drug Delivery 20:6, pages 815-830.
Read now
Read now
Cisio De Oliveira Brandao, Sandra Lewis, Darcie Sandschafer & Jeffrey Crawford. (2023) Two decades of pegfilgrastim: what have we learned? Where do we go from here?. Current Medical Research and Opinion 39:5, pages 707-718.
Read now
Read now
Jakob Lange, Andreas Schneider, Christoph Jordi, Michael Lau & Timothy Disher. (2021) Formative Study on the Wearability and Usability of a Large-Volume Patch Injector. Medical Devices: Evidence and Research 14, pages 363-377.
Read now
Read now
Ali McBride, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky & Ivo Abraham. (2021) Same-Day Versus Next-Day Pegfilgrastim or Pegfilgrastim-Cbqv in Patients with Lymphoma Receiving CHOP-Like Chemotherapy. Future Oncology 17:26, pages 3485-3497.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of Medical Economics 24:1, pages 598-606.
Read now
Read now
Karen MacDonald, Ali McBride, Neda Alrawashdh & Ivo Abraham. (2020) Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. Journal of Medical Economics 23:12, pages 1466-1476.
Read now
Read now
Ali McBride, Andriy Krendyukov, Nicola Mathieson, Kim Campbell, Sanjeev Balu, Maja Natek, Karen MacDonald & Ivo Abraham. (2020) Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. Journal of Medical Economics 23:1, pages 28-36.
Read now
Read now
Andreas Schneider, Harald Kolrep, Christoph Jordi, Philipp Richard, Hanns-Peter Horn & Jakob Lange. (2019) How to prevent medication errors: a multidimensional scaling study to investigate the distinguishability between self-injection platform device variants. Expert Opinion on Drug Delivery 16:8, pages 883-894.
Read now
Read now
Andreas E. Schneider & Jakob Lange. (2018) Pen devices for self-injection: contrasting measured injection force with users’ perceived ease of injection. Expert Opinion on Drug Delivery 15:2, pages 115-125.
Read now
Read now
Articles from other publishers (10)
Victor Pera, Frauke van Vaerenbergh, Jan A. Kors, Erik M. van Mulligen, Rowan Parry, Marcel de Wilde, Lies Lahousse, Johan van der Lei, Peter R. Rijnbeek & Katia M. C. Verhamme. (2023) Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration's Adverse Event Reporting System. Pharmacoepidemiology and Drug Safety 33:1.
Crossref
Crossref
Jacob Hobbs, Jan Lowe, Abigale Ferdinand, Anna Shook, Bradley Beck, Danielle Blais, Cole Borchardt & Bing Xu. (2022) Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis. Journal of Oncology Pharmacy Practice 29:8, pages 1853-1861.
Crossref
Crossref
Sophia Z. Humphreys, Robert B. Geller & Paul Walden. (2022) Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit. Oncology and Therapy 10:2, pages 351-361.
Crossref
Crossref
Ching-Yu WangHaesuk ParkCoy D HeldermonScott M VouriJoshua D Brown. (2022) Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population. Journal of Managed Care & Specialty Pharmacy 28:7, pages 795-802.
Crossref
Crossref
Lucas Maahs, Amy Tang, Zaid Al Saheli, Brigid Jacob, Rishika Polasani & Clara Hwang. (2020) Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia. Journal of Oncology Pharmacy Practice 28:1, pages 17-23.
Crossref
Crossref
Aylin Yucel, Anne Skalicky, Olabimpe Ruth Eseyin, Emre Yucel, Rajesh Belani & Mark Bensink. (2021) Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF). Journal of Patient-Reported Outcomes 5:1.
Crossref
Crossref
Michael Metz, Dieter Semsek, Gunther Rogmans, Ulrich Hutzschenreuter, Thomas Fietz, Johanna Harde, Stefan Zacharias, Carsten Hielscher, Andreas Lorenz, Mark-Oliver Zahn, Dagmar Guth, Steffen Liebers, Michael Berghorn, Sina Grebhardt, Christiane D. Matillon, Gerlinde Egerer & Karin Potthoff. (2021) Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Supportive Care in Cancer 29:11, pages 6633-6643.
Crossref
Crossref
Ali McBrideKim CampbellEdward LiBridgette SchroaderDavid CampbellWeijia Wang. (2021) Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1230-1238.
Crossref
Crossref
Ali McBride, Karen MacDonald & Ivo Abraham. (2021) Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leukemia Research 106, pages 106591.
Crossref
Crossref
Jolly Patel, Rebecca Ann Rainess, Miranda J. Benfield, Kate M. L. Rogers, Donald C. Moore, Chris Larck & Justin R. Arnall. (2019) Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support. Hospital Pharmacy 56:2, pages 77-80.
Crossref
Crossref